CL2016000232A1 - Estabilización de polipéptidos que contienen fragmentos cristalizables - Google Patents

Estabilización de polipéptidos que contienen fragmentos cristalizables

Info

Publication number
CL2016000232A1
CL2016000232A1 CL2016000232A CL2016000232A CL2016000232A1 CL 2016000232 A1 CL2016000232 A1 CL 2016000232A1 CL 2016000232 A CL2016000232 A CL 2016000232A CL 2016000232 A CL2016000232 A CL 2016000232A CL 2016000232 A1 CL2016000232 A1 CL 2016000232A1
Authority
CL
Chile
Prior art keywords
stabilization
polypeptides containing
containing crystallizable
crystallizable fragments
replacement
Prior art date
Application number
CL2016000232A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Frederick W Jacobsen
Jennifer Lavallee
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2016000232A1 publication Critical patent/CL2016000232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Abstract

POLIPÉPTIDO QUE COMPRENDE UNA REGIÓN Fc DE ANTICUERPO CON UNA DELECIÓN O SUSTITUCIÓN DE UNA O MÁS CISTEÍNAS EN LA REGIÓN BISAGRA Y UNA SUSTITUCIÓN CON UN RESIDUO QUE CONTIENE SULFIHIDRILO EN UNO A MÁS AMINOÁCIDOS EN LA INTERFASE CH3; ÁCIDO NUCLEICO; VECTOR; CÉLULA HOSPEDERA; MÉTODO DE ELABORACIÓN; Y COMPOSICIÓN FARMACÉUTICA.
CL2016000232A 2013-07-31 2016-01-28 Estabilización de polipéptidos que contienen fragmentos cristalizables CL2016000232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31

Publications (1)

Publication Number Publication Date
CL2016000232A1 true CL2016000232A1 (es) 2016-09-02

Family

ID=52432568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000232A CL2016000232A1 (es) 2013-07-31 2016-01-28 Estabilización de polipéptidos que contienen fragmentos cristalizables

Country Status (15)

Country Link
US (3) US20160193295A1 (es)
EP (1) EP3027647A4 (es)
JP (2) JP2016526909A (es)
KR (3) KR20160034404A (es)
CN (1) CN105658664A (es)
AU (3) AU2014296215A1 (es)
BR (1) BR112016002219A2 (es)
CA (1) CA2919076C (es)
CL (1) CL2016000232A1 (es)
EA (1) EA035319B1 (es)
HK (1) HK1224203A1 (es)
IL (1) IL243690B (es)
MX (2) MX2016001165A (es)
SG (1) SG11201600734YA (es)
WO (1) WO2015017548A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
UA123432C2 (uk) 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
MD20170035A2 (ro) 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
EP3463451A1 (en) 2016-05-26 2019-04-10 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10
MX2019007611A (es) * 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
WO2018144784A1 (en) * 2017-02-01 2018-08-09 Smet Pharmaceutical Inc. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
IL271837B2 (en) * 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd Novel therapeutic enzyme fusion protein and use thereof
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
BR112020012346A2 (pt) * 2017-12-22 2020-11-24 Hanmi Pharm. Co., Ltd. proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
IL280467B2 (en) 2018-08-03 2025-03-01 Amgen Res Munich Gmbh Antibody constructs for CLDN18.2 and CD3
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
US20220259329A1 (en) 2019-06-07 2022-08-18 Amgen Inc. Bispecific binding constructs
CR20220107A (es) * 2019-09-18 2022-04-25 Novartis Ag Proteínas de fusión nkg2d y sus usos
PT4065585T (pt) 2019-11-25 2025-09-30 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
AU2020400805B2 (en) * 2019-12-11 2024-03-28 Lg Chem, Ltd. Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
CN116096736A (zh) * 2020-08-14 2023-05-09 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
AU2021329742B2 (en) * 2020-08-21 2025-12-11 Fatiabgen Inc. Antibody fragment consisting of heavy chain and light chain constant regions in which gamma constant region (CΓ1) and epsilon constant region (CE2-4) are fused, and use thereof
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
MX2023005063A (es) * 2020-11-02 2023-05-12 Attralus Inc Proteinas de fusion sap fc y metodos de uso.
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
EP4256336A1 (en) * 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CN115925984A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN119080948B (zh) * 2023-04-17 2025-05-27 北京康乐卫士生物技术股份有限公司 带状疱疹病毒疫苗的嵌合抗原及其应用
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) * 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2005282700A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006317242A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AU2010321720B2 (en) * 2009-11-23 2017-03-02 Amgen Inc. Monomeric antibody Fc
MX379481B (es) * 2010-12-06 2025-03-11 Seagen Inc Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer

Also Published As

Publication number Publication date
JP7344858B2 (ja) 2023-09-14
CA2919076A1 (en) 2015-02-05
US20190192628A1 (en) 2019-06-27
IL243690A0 (en) 2016-04-21
EP3027647A2 (en) 2016-06-08
KR20230141929A (ko) 2023-10-10
AU2020200329A1 (en) 2020-02-06
AU2022201204A1 (en) 2022-03-17
CA2919076C (en) 2024-01-30
AU2022201204B2 (en) 2025-01-02
WO2015017548A2 (en) 2015-02-05
EA035319B1 (ru) 2020-05-27
JP2021019598A (ja) 2021-02-18
US20160193295A1 (en) 2016-07-07
SG11201600734YA (en) 2016-02-26
MX2016001165A (es) 2016-06-29
KR20250152665A (ko) 2025-10-23
IL243690B (en) 2022-09-01
CN105658664A (zh) 2016-06-08
EA201690299A1 (ru) 2016-11-30
MX2022008013A (es) 2022-07-27
BR112016002219A2 (pt) 2017-09-12
JP2016526909A (ja) 2016-09-08
KR20160034404A (ko) 2016-03-29
US20250325631A1 (en) 2025-10-23
EP3027647A4 (en) 2017-01-04
WO2015017548A3 (en) 2015-11-05
AU2014296215A1 (en) 2016-02-11
HK1224203A1 (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
CL2016000232A1 (es) Estabilización de polipéptidos que contienen fragmentos cristalizables
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
BR112018073628A2 (pt) anticorpos antimiostatina e métodos de utilização
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
ZA201906039B (en) Recombinant yeast host cells expressing cell-associated heterologous proteins
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
PH12016500239A1 (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
EP3497215A4 (en) CELL PERMEABLES (CP) -CAS9 RECOMBINANT PROTEIN AND USES THEREOF
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
BR112015024587A2 (pt) variante de região fc
EA201791918A1 (ru) Модификация белков клеток-хозяев
EP3044323A4 (en) Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
BR112017006112A2 (pt) formulação de proteína de fusão recombinante
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
MX394682B (es) Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa.
PE20152020A1 (es) Dominios gla como agentes de direccionamiento
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
PE20151757A1 (es) Anticuerpos anti-cd52
MX2018003445A (es) Expresion de proteinas que contienen fc.
IL284803A (en) Methods of producing multimeric proteins in eukaryotic host cells
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения
MX2018007298A (es) Variantes con mejores propiedades de polipéptidos de fusión relacionados con omega-hidroxilasa.
MX384990B (es) Selectividad eficaz de proteínas recombinantes.